Materialise shares declined 3.7% following the Q1 report, driven primarily by cautious outlook commentary and the transfer of non-core businesses, which signals a strategic refocus but also raises near-term uncertainty around segment revenue growth and margin trajectory.

• Materialise completed the transfer of RapidFit and its eyewear business to management teams, exiting these non-core units to sharpen focus on core segments; financial terms were undisclosed.
• The Medical segment expanded its cranio-maxillofacial portfolio with new custom-made PEEK implants, providing surgeons with an alternative to Titanium and enhancing the integrated digital workflow.
• Launched OrthoView 3D Hip, extending surgical planning capabilities from 2D X-ray to CT scan-based workflows, leveraging proprietary segmentation and modeling technologies.
• Software innovation continued with the rollout of CO-AM Professional, aimed at automating additive manufacturing operations; early access and presales are underway, with full availability expected mid-year.
• Despite product launches and structural moves, management’s cautious tone regarding outlook and strategic divestitures likely weighed on investor sentiment, contributing to the share price decline.